Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 13, 2025

NCI-H28

RRID:CVCL_1555
Type: Cell Line

Proper Citation

(RRID:CVCL_1555)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1555

Proper Citation: (RRID:CVCL_1555)

Sex: Male

Defining Citation: PMID:1568228, PMID:6272398, PMID:8183553, PMID:8806092, PMID:11030152, PMID:11070089, PMID:11464291, PMID:16630136, PMID:17270034, PMID:20164919, PMID:21245096, PMID:21642991, PMID:22460905, PMID:23830731, PMID:24926545, PMID:25485619, PMID:25877200, PMID:25902174, PMID:26011428, PMID:26589293, PMID:27397505, PMID:28196595, PMID:28553954, PMID:30894373, PMID:31068700, PMID:31803961, PMID:35839778

Comments: Caution: It is not clear if this cell line originate from an epithelioid or sarcomatoid mesothelioma as there are contradictory reports concerning its exact nature., Caution: According to ATCC the ethnicity of the donor is White, but exome analysis finds it to be mostly of African lineage., Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Omics: Array-based CGH., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: NCI-H28

Synonyms: H28, H-28, NCIH28, HUT-28, HUT 28, HuT 28, HUT28, Hut28, HuT28

Cross References: CLO:CLO_0008079, EFO:EFO_0006686, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5820, BioSample:SAMN03471010, BioSample:SAMN10987612, BioSamples:SAMEA100874, cancercelllines:CVCL_1555, Cell_Model_Passport:SIDM00720, ChEMBL-Cells:CHEMBL3308775, ChEMBL-Targets:CHEMBL1075541, Cosmic:688059, Cosmic:733814, Cosmic:877108, Cosmic:877350, Cosmic:886387, Cosmic:908470, Cosmic:980995, Cosmic:1032386, Cosmic:1146909, Cosmic:1152495, Cosmic:1481543, Cosmic:1522766, Cosmic:1541208, Cosmic:1749556, Cosmic:1963325, Cosmic:1995572, Cosmic:2474149, Cosmic:2758840, Cosmic:2758998, Cosmic:2759230, Cosmic-CLP:908470, DepMap:ACH-000648, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:908470, GEO:GSM171870, GEO:GSM171871, GEO:GSM434272, GEO:GSM726267, GEO:GSM794268, GEO:GSM850284, GEO:GSM887425, GEO:GSM888504, GEO:GSM1670236, IARC_TP53:21567, IARC_TP53:23623, IGRhCellID:H28GEO, KCLB:90028, LiGeA:CCLE_571, PharmacoDB:NCIH28_1099_2019, PRIDE:PXD030304, Progenetix:CVCL_1555, PubChem_Cell_line:CVCL_1555, Wikidata:Q54908002

ID: CVCL_1555

Record Creation Time: 20250131T201501+0000

Record Last Update: 20250131T203141+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H28.

Warning: Discontinued: KCLB; 90028
Caution: It is not clear if this cell line originate from an epithelioid or sarcomatoid mesothelioma as there are contradictory reports concerning its exact nature., Caution: According to ATCC the ethnicity of the donor is White, but exome analysis finds it to be mostly of African lineage., Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Omics: Array-based CGH., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Hirai S, et al. (2024) Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells. Molecular cancer therapeutics, 23(2), 212.

Hagiyama M, et al. (2024) Efficient intracellular drug delivery by co-administration of two antibodies against cell adhesion molecule 1. Journal of controlled release : official journal of the Controlled Release Society, 371, 603.

Hillen H, et al. (2024) A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models. Molecular cancer therapeutics, 23(1), 3.

Pandey GK, et al. (2023) Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma. Cell reports. Medicine, 4(2), 100915.

Maille E, et al. (2022) A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial. International journal of cancer, 150(11), 1889.

Lappin KM, et al. (2022) Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors. Cancer research, 82(5), 819.

Gonzalez VD, et al. (2021) High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment. Cell reports, 36(9), 109632.

Yang H, et al. (2021) NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma. Cancers, 13(7).

Oehl K, et al. (2021) Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(8), 2277.

Bénard M, et al. (2021) Optimization of Advanced Live-Cell Imaging through Red/Near-Infrared Dye Labeling and Fluorescence Lifetime-Based Strategies. International journal of molecular sciences, 22(20).

Yang H, et al. (2020) Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma. Cancers, 12(8).

Xu D, et al. (2019) Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma. Cancers, 11(10).

Kolluri KK, et al. (2018) Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells. eLife, 7.